GPC Stock Recent News

A potential 15% corporate tax rate could trigger a significant rally, similar to the 2017 euphoria, boosting S&P 500 earnings by 4%. Focus on undervalued, high-quality dividend aristocrats in consumer discretionary, materials and industrials sectors, which would benefit most from the tax cuts. These five aristocrats offer a 3.2% yield, 10% annual dividend growth, and 33% upside potential in the next year, even without tax cuts, and 38% with tax cuts.

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data demonstrated that the development candidate can successfully create CAR-M directly in vivo, reprogramming endogenous myeloid cells to target and destroy Glypican-3 ("GPC3"), expressing cancer cells.

Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA , Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for the treatment of hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data will be presented in a poster session at the Society for Immunotherapy of Cancer ("SITC") Annual Meeting in Houston, Texas, on November 8, 2024.

SPY's 5 month positive streak comes to an end in October as it posts a loss of 0.89%. The top 10 stocks on the watchlist for November 2024 offer a 3.61% dividend yield, more than double the S&P 500. My top 10 list of high dividend yield stocks has generated an annualized rate of return of 17.27% since its inception in November 2020.

Assessing risk vs. reward is crucial for stock investing; Genuine Parts Company's recent 20% drop prompts a re-evaluation of its current investment potential. Treat Genuine Parts' current downturn as recession-like; historical data suggests deeper price drops are possible given past P/E ratios and earnings declines. GPC is a slow-growth business; it should only be bought at a deep discount for potential mean reversion gains, not for long-term holding.

Explore how Genuine Parts' (GPC) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Shares fell after the company lowered 2024 earnings expectations.

I downgrade Genuine Parts Company stock from buy to hold due to poor 3Q24 performance and a weak macroeconomic outlook impacting both APG and IPG segments. 3Q24 results showed disappointing comparable sales growth, with APG and IPG segments underperforming, leading to a significant miss on EPS estimates. The outlook remains bleak, with no signs of improvement in consumer spending and industrial production.

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic centers for its clinical trial evaluating the safety and efficacy of NY-303, its GPC3-targeting NK Engager bispecific antibody, as a monotherapy for the treatment of hepatocellular carcinoma in patients not responding to first-line immunotherapy.

Genuine Parts Company experienced a significant 20% drop in stock value, now trading at a valuation below 12.2x P/E normalized with a yield above 3.53%. Despite the drop, Genuine Parts Company remains a stable, nearly 100-year-old business with a BBB rating and a market cap over $15B, not facing bankruptcy. The decline was triggered by 3Q24 results, but the company's fundamentals in automotive and industrial replacement parts remain strong, suggesting potential upside.